Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

Genecept Assay and Adverse Effects of Antidepressants

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02883660
Recruitment Status : Completed
First Posted : August 30, 2016
Last Update Posted : March 16, 2018
Sponsor:
Information provided by (Responsible Party):
Thomas Jefferson University

Brief Summary:
The purpose of this study is to determine whether patients who have been prescribed antidepressant medications and have experienced significant adverse effects are more likely to be poor metabolizers on the CYP450 (CYP2B6, CYP2D6, CYP2C19, CYP3A4/5+) drug metabolizing enzymes and/or homozygous for the short allele of the serotonin transporter (SLC6A4) compared to patients who took an antidepressant medication and did not experience significant adverse effects but also had minimal or no response to the medication. The target medications being studied include escitalopram, citalopram, paroxetine, fluvoxamine, venlafaxine, duloxetine, bupropion, vortioxetine, vilazodone, and levomilnacipran only.

Condition or disease Intervention/treatment
Depression Adverse Effects Genetic: Genocept Assay

Detailed Description:
Genetic variations in the CYP2B6, CYP2D6, CYP2C19, and CYP3A4/5+ drug metabolizing enzymes are responsible for metabolism of a large number of psychiatric and nonpsychiatric medications. Variations in the genes encoding for these enzymes can alter their activity resulting in unexpectedly high or low serum levels of the drug leading potentially to change in both efficacy and adverse events. The serotonin transporter protein is a presynaptic transmembrane protein responsible for serotonin reuptake. The "short" form of the serotonin transporter promoter (SLC6A4) is associated with reduced activity of the of the transporter. Patients who are homozygous for the "short" alleles of SLC6A4 may be more likely to have with poor response, slow response, and greater adverse events with serotonergic medications. The target medications being studied include escitalopram, citalopram, paroxetine, fluvoxamine, venlafaxine, duloxetine, bupropion, vortioxetine, vilazodone, and levomilnacipran only.

Layout table for study information
Study Type : Observational
Actual Enrollment : 74 participants
Observational Model: Case-Control
Time Perspective: Retrospective
Official Title: Genecept Assay and Adverse Effects of Antidepressants
Study Start Date : February 2013
Actual Primary Completion Date : July 1, 2017
Actual Study Completion Date : February 1, 2018

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Antidepressants

Group/Cohort Intervention/treatment
Cases
patients who had empirically defined "increased AEs" on one of the specified antidepressants (SSRIs/ SNRIs). This group will get the Genecept Assay, which is a battery of pharmacogenetic tests relevant to psychiatry.
Genetic: Genocept Assay
battery of pharmacogenetic tests relevant to psychiatry

Controls
patients who did not have empirically defined "increased AEs" with an index antidepressant (one of the specified SSRIs/ SNRIs) AND were "nonresponders" to that antidepressant. This group will get the Genecept Assay, which is a battery of pharmacogenetic tests relevant to psychiatry.
Genetic: Genocept Assay
battery of pharmacogenetic tests relevant to psychiatry




Primary Outcome Measures :
  1. Poor metabolizers have more side effects [ Time Frame: through study completion, approximately 2 years ]
    Our primary aim is to test the hypothesis that a statistically significantly higher proportion of Cases than Controls will be poor metabolizers on CYP450 isoenzymes (CYP2B6, CYP2D6, CYP2C19, CYP3A4/5+).

  2. Homozygenous for short allele of SLC6A4 will result in more side effects [ Time Frame: through study completion, approximately 2 years ]
    Our co-primary aim is to test the hypothesis that a statistically significantly higher proportion of Cases than Controls will be homozygenous for the short allele of SLC6A4.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population
One hundred (100) subjects aged 18 years or older, currently or in the past on one of the target antidepressants, will be recruited into this study.
Criteria

Inclusion Criteria:

  1. Age 18 years or older
  2. Able to give informed consent prior to the initiation of any protocol required procedures.
  3. Subject must be able to understand the nature of the study, agree to comply with the study procedures, and communicate about medical history to the study personnel.
  4. Subject was treated with one of the following "target antidepressants:" Escitalopram, citalopram, paroxetine, fluvoxamine, venlafaxine, duloxetine, bupropion, vortioxetine, vilazodone, and levomilnacipran. Rationale: These antidepressants are primarily metabolized by CYP isoenzymes that will be assessed. Antidepressants like sertraline, fluoxetine, and mirtazapine are metabolized by multiple CYP isoenzymes and therefore are less likely to be significantly affected by metabolizer status on a particular CYP isoenzyme. For patients who have been treated with multiple antidepressants, the antidepressant that was associated with the greatest overall burden of AEs will be selected as the target antidepressant.

5a. Study group: "Increased AEs" currently or in the past on one of the target antidepressants as operationally defined as either A or B: A) One or more AEs that were moderate/severe OR three or more AEs that were mild occurring on less than the usual minimum recommended dose of the antidepressant, or B) Three or more AEs that were moderate/severe OR five or more AEs that were mild on a dose of the antidepressant within the usual recommended dose 5b. Control group: Both A and B A. Less than 30% reduction in the severity of depression after treatment for at least 6 weeks B. Minimal or no AEs on that antidepressant

Exclusion Criteria:

  1. Subjects on antidepressants other than those specified in the inclusion criteria.
  2. Subjects for whom it is unclear which medication caused the adverse events
  3. Subjects for whom participation in the study would be detrimental to their mental of physical health based on investigator's opinion
  4. Subjects who have had a medical condition that, in the investigator's judgment, may be causing the reported adverse events
  5. Prisoners or patients who are involuntarily incarcerated

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02883660


Locations
Layout table for location information
United States, Pennsylvania
Thomas Jefferson University
Philadelphia, Pennsylvania, United States, 19107
Sponsors and Collaborators
Thomas Jefferson University
Investigators
Layout table for investigator information
Principal Investigator: William Jangro, MD Thomas Jefferson University

Layout table for additonal information
Responsible Party: Thomas Jefferson University
ClinicalTrials.gov Identifier: NCT02883660     History of Changes
Other Study ID Numbers: 13P.25
First Posted: August 30, 2016    Key Record Dates
Last Update Posted: March 16, 2018
Last Verified: March 2018
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Yes
Plan Description: no plan to make IPD available

Keywords provided by Thomas Jefferson University:
genetics
Antidepressants

Additional relevant MeSH terms:
Layout table for MeSH terms
Antidepressive Agents
Psychotropic Drugs